Ultragenyx Pharmaceutical Inc Dossier
Qualitative Analysis
Business overview
Ultragenyx Pharmaceutical Inc. is a clinical-stage and commercial biopharmaceutical company focused on the identification, development, and commercialization of novel therapies for serious rare and ultra-rare genetic diseases. Founded in 2010 by pediatric geneticist Emil Kakkis, the company targets disorders with high unmet medical needs and clear biological pathways. Its diverse portfolio spans multiple drug modalities, including biologics, small molecules, and gene therapies. Key approved products include Crysvita (burosumab) for X-linked hypophosphatemia, Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders, and Mepsevii (vestronidase alfa) for Mucopolysaccharidosis VII. The company operates globally with offices in Novato, California, and a presence in Latin America and Europe.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiated in February 2026, this plan includes a 10% workforce reduction (eliminating approximately 130 positions) and a curtailment of certain early-stage research and manufacturing activities (such as UX143 manufacturing) to reduce operating expenses.
Expected impact: Designed to keep the company on its path to profitability in 2027 by keeping 2026 combined R&D and SG&A expenses flat to down low-single digits and reducing 2027 combined expenses by at least 15% compared to 2025.
Scaling international launches and expanding access for Crysvita, Dojolvi, Mepsevii, and Evkeeza, with a particular focus on penetrating Asia-Pacific markets (such as Japan and South Korea) and Latin America.
Expected impact: Aims to diversify revenue streams, reduce dependence on North American sales, and capture market share in the global XLH market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of GeneTx followed an initial 2019 partnership and option agreement. The acquisition secured full global rights to GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome, marking a significant expansion into neurogenetic disorders.
Financial impact: Initial upfront option payment of $20 million in 2019, followed by a $75 million option exercise payment in July 2022 (total purchase consideration of $91.2 million including working capital adjustments), with potential future milestone and royalty payments.
Strategic Partnerships
A long-running global collaboration established in 2013 to develop and commercialize Crysvita (burosumab) for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Primary commercial responsibility in the US and Canada reverted to Kyowa Kirin in 2023, while Ultragenyx continues to lead commercial efforts in Latin America and Turkey.
Terms: The parties share development costs and split profits 50/50 in the profit-share territory (US/Canada) until April 2023, after which primary commercial responsibility reverted to Kyowa Kirin. Ultragenyx receives royalties on sales. In November 2025, Ultragenyx sold an additional 25% of its future Crysvita royalty interest in the US and Canada to OMERS for $400 million upfront.
Collaboration established in December 2020 to develop and commercialize setrusumab (UX143) for the treatment of osteogenesis imperfecta (OI). Ultragenyx leads and funds global development to approval, holding commercial rights in the US and the rest of the world (excluding Europe and the UK, where Mereo retains rights).
Terms: Mereo received $50 million upfront and is eligible for up to $254 million in clinical, regulatory, and commercial milestones. Ultragenyx will pay tiered double-digit royalties to Mereo on net sales outside Europe/UK, and Mereo will pay a fixed double-digit royalty to Ultragenyx on net sales in Europe/UK.